Biotech Values

[jbog]

Revance announces departure of CFO, CBO Lauren Silvernail Revance Therapeutics announced that Lauren Silvernail has resigned as Revance's CFO and Chief Business Officer, effective as of May 29, 2018, to pursue a CFO ole at an aesthetics company in Orange County, California, where she resides. Her departure is not based on any disagreement with the company's accounting principles or practices, internal controls or financial statement disclosures. Following Silvernail's resignation, certain members of management and the company's existing finance team will assume the duties and responsibilities of the office on an interim basis. Revance is initiating a search for its next CFO, who will play an important role as the company prepares for the commercialization of its lead product candidate, DaxibotulinumtoxinA for Injection.

Read more at:
https://thefly.com/landingPageNews.php?id=2737234

This ends the positivism of her stock transactions.